The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Open accessAbstract
In schizophrenia patients, glutathione dysregulation at the gene, protein and functional levels, leads to N-methyl-D-aspartate (NMDA) receptor hypofunction. These patients also exhibit deficits in auditory sensory processing that manifests as impaired mismatch negativity (MMN), which is an auditory evoked potential (AEP) component related to NMDA receptor function. N-acetyl-cysteine (NAC), a glutathione precursor, was administered to patients to determine whether increased levels of brain glutathione would improve MMN and by extension NMDA function. A randomized, double-blind, cross-over protocol was conducted, entailing the administration of NAC (2 g/day) for 60 days and then placebo for another 60 days (or vice versa). 128-channel AEPs were recorded during a frequency oddball discrimination task at protocol onset, at the point of cross-over, and at the end of the study. At the onset of the protocol, the MMN of patients was significantly impaired compared to sex- and age- matched healthy controls (p=0.003), without any evidence of concomitant P300 component deficits. Treatment with NAC significantly improved MMN generation compared with placebo (p=0.025) without any measurable effects on the P300 component. MMN improvement was observed in the absence of robust changes in assessments of clinical severity, though the latter was observed in a larger and more prolonged clinical study. This pattern suggests that MMN enhancement may precede changes to indices of clinical severity, highlighting the possible utility AEPs as a biomarker of treatment efficacy. The improvement of this functional marker may indicate an important pathway towards new therapeutic strategies that target glutathione dysregulation in schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, NAC normalized neuronal activity and connectivity and improved mismatch-negativity (Lavoie et al., 2008), an auditory-related, NMDA-dependent evoked potential typically impaired in schizophrenia (Umbricht et al., 2000).”
From Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? (2016) · cites this paper as Lavoie et al., 2008
In the citing paper
“Published studies have revealed beneficial effects in schizophrenia patients as an add-on to maintenance medication [100][101][102][103] and ongoing studies are following up their results and including additional metrics of efficacy such as brain GSH imaging in order to reflect the BBB permeability analyses of NAC that have been performed in rodents 104 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [102]
In the citing paper
“Other compounds that may reverse MMN deficits in schizophrenia include N-acetylcysteine, a precursor of the brain antioxidant glutathione (59) and D-serine, an endogenous NMDAR modulator (60).”
From Sensory Processing Dysfunction in the Personal Experience and Neuronal Machinery of Schizophrenia (2015) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meister, A., & Anderson, M. E. (1983) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.52.070183.003431 · Cited by 5,694
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Early selective-attention effect on evoked potential reinterpreted
Näätänen, R., Gaillard, A. W. K., & Mäntysalo, S. (1978) · Acta Psychologica · doi:10.1016/0001-6918(78)90006-9 · Cited by 2,725
Diagnostic Interview for Genetic Studies
Nürnberger, J. I. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950110009002 · Cited by 2,075
Michel, C., Murray, M. M., Lantz, G., Gonzalez, S., Spinelli, L., & de Peralta, R. G. (2004) · Clinical Neurophysiology · doi:10.1016/j.clinph.2004.06.001 · Cited by 1,771
Self-citationDecreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
Reference-free identification of components of checkerboard-evoked multichannel potential fields
Lehmann, D., & Skrandies, W. (1980) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(80)90419-8 · Cited by 1,595
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia
Garey, L. J., Ong, W., Patel, T. S., Kanani, M., Davis, A., Mortimer, A. M., Barnes, T., & Hirsch, S. R. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.4.446 · Cited by 719
Cited by
Sorted by citations
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Glutathione dysregulation and the etiology and progression of human diseases
Ballatori, N., Krance, S. M., Notenboom, S., Shi, S., Tieu, K., & Hammond, C. L. (2009) · Biological Chemistry · doi:10.1515/bc.2009.033 · Cited by 1,145
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
Self-citationThe chemistry and biological activities of N-acetylcysteine
Samuni, Y., Goldstein, S., Dean, O. M., & Berk, M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.016 · Cited by 876
Self-citationTowards the utilization of EEG as a brain imaging tool
Michel, C. M., & Murray, M. M. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.12.039 · Cited by 774
Self-citationRushworth, G. F., & Megson, I. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.006 · Cited by 724
Ketamine-Induced Loss of Phenotype of Fast-Spiking Interneurons Is Mediated by NADPH-Oxidase
Behrens, M. M., Ali, S. S., Dao, D. N., Lucero, J., Shekhtman, G., Quick, K. L., & Dugan, L. L. (2007) · Science · doi:10.1126/science.1148045 · Cited by 585
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 584
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Self-citationN-Acetylcysteine (NAC): Impacts on Human Health
Tenório, M. C. D. S., Graciliano, N. G., Moura, F. A., Oliveira, A. C. M. D., & Goulart, M. O. F. (2021) · Antioxidants · doi:10.3390/antiox10060967 · Cited by 526
Berk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Self-citationN-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
Dean, O., Giorlando, F., & Berk, M. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100057 · Cited by 494
Self-citationOxidative stress in schizophrenia: An integrated approach
Bitanihirwe, B. K. Y., & Woo, T.-U. W. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.008 · Cited by 482
The promise of N-acetylcysteine in neuropsychiatry
Berk, M., Malhi, G. S., Gray, L. J., & Dean, O. M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.001 · Cited by 434
Self-citationErickson, M. A., Ruffle, A., & Gold, J. M. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.025 · Cited by 426
Näätänen, R., Kujala, T., Escera, C., Baldeweg, T., Kreegipuu, K., Carlson, S., & Ponton, C. W. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.09.020 · Cited by 447
N -acetylcysteine for antioxidant therapy: pharmacology and clinical utility
Dodd, S., Dean, O., Copolov, D. L., Malhi, G. S., & Berk, M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14728220802517901 · Cited by 413
Self-citationSensory Processing Dysfunction in the Personal Experience and Neuronal Machinery of Schizophrenia
Javitt, D. C., & Freedman, R. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13121691 · Cited by 403
Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 414
Redox dysregulation, neurodevelopment, and schizophrenia
Do, K. Q., Cabungcal, J. H., Frank, A., Steullet, P., & Cuenod, M. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.05.001 · Cited by 384
Self-citationEmerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Javitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs069 · Cited by 322
Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis
Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304
Molecular Strategies for Targeting Antioxidants to Mitochondria: Therapeutic Implications
Apostolova, N., & Víctor, V. M. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5952 · Cited by 311
Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases
Tardiolo, G., Bramanti, P., & Mazzon, E. (2018) · Molecules · doi:10.3390/molecules23123305 · Cited by 299
Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View
Yao, J. K., & Keshavan, M. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3603 · Cited by 285
Steullet, P., Cabungcal, J. H., Monin, A., Dwir, D., O'Donnell, P., Cuenod, M., & Do, K. Q. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2014.06.021 · Cited by 262
Self-citationMeyer, U., Schwarz, M., & Müller, N. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.003 · Cited by 262
Carbon, M., & Correll, C. U. (2014) · CNS Spectrums · doi:10.1017/s1092852914000601 · Cited by 281
Smaga, I., Niedzielska, E., Gawlik, M., Moniczewski, A., Krzek, J., Przegaliński, E., Pera, J., & Filip, M. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.12.015 · Cited by 252
Glutamatergic theories of schizophrenia.
Javitt, D. C. (2010) · PubMed · Cited by 248
Oxidative Stress in Schizophrenia
Grabnar, I., Vovk, T., Plesničar, B. K., & Boskovic, M. (2011) · Current Neuropharmacology · doi:10.2174/157015911795596595 · Cited by 256
Näätänen, R., Kujala, T., Kreegipuu, K., Carlson, S., Escera, C., Baldeweg, T., & Ponton, C. W. (2011) · Brain · doi:10.1093/brain/awr064 · Cited by 252
Oxidative Stress‐Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives
Ermakov, E. A., Dmitrieva, E. M., Parshukova, D. A., Kazantseva, D. V., Vasilieva, A. R., & Smirnova, L. P. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8881770 · Cited by 256
Näätänen, R., & Kähkönen, S. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009322 · Cited by 233
Cabungcal, J.-H., Steullet, P., Kraftsik, R., Cuenod, M., & Do, K. Q. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.09.020 · Cited by 232
The neurobiology and treatment of first-episode schizophrenia
Kahn, R. S., & Sommer, I. E. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.66 · Cited by 219
Mismatch Negativity (MMN) as an Index of Cognitive Dysfunction
Näätänen, R., Sussman, E. S., Salisbury, D. F., & Shafer, V. L. (2014) · Brain Topography · doi:10.1007/s10548-014-0374-6 · Cited by 244
Thomas, M. L., Green, M. F., Hellemann, G., Sugar, C. A., Tarasenko, M., Calkins, M. E., Greenwood, T. A., Gur, R. E., Gur, R. C., Lazzeroni, L. C., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2980 · Cited by 206
Bridges, R., Lutgen, V., Lobner, D., & Baker, D. A. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003889 · Cited by 205
Juvenile Antioxidant Treatment Prevents Adult Deficits in a Developmental Model of Schizophrenia
Cabungcal, J.-H., Counotte, D. S., Lewis, E. M., Tejeda, H. A., Piantadosi, P., Pollock, C., Calhoon, G. G., Sullivan, E. M., Presgraves, E., Kil, J., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.028 · Cited by 204
Self-citationMatsuzawa, D., Obata, T., Shirayama, Y., Nonaka, H., Kanazawa, Y., Yoshitome, E., Takanashi, J., Matsuda, T., Shimizu, E., Ikehira, H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001944 · Cited by 201
Light, G. A., Swerdlow, N. R., Thomas, M. L., Calkins, M. E., Green, M. F., Greenwood, T. A., Gur, R. E., Gur, R. C., Lazzeroni, L. C., Nuechterlein, K. H., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.09.042 · Cited by 198
Correll, C. U., Hauser, M., Auther, A. M., & Cornblatt, B. A. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02235.x · Cited by 204
Using glutamate homeostasis as a target for treating addictive disorders
Reissner, K. J., & Kalivas, P. W. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833d41b2 · Cited by 201
Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194
Light, G. A., Swerdlow, N. R., Rissling, A. J., Radant, A. D., Sugar, C. A., Sprock, J., Pela, M., Geyer, M. A., & BRAFF, D. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039434 · Cited by 193
Inflammation in schizophrenia: A question of balance
Leza, J. C., García‐Bueno, B., Bioque, M., Arango, C., Parellada, M., Kim, Q., O’Donnell, P., & Bernardo, M. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.05.014 · Cited by 188
Berk, M., Dean, O., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B. S., Kohlmann, K., Jeavons, S., Hewitt, K., Allwang, C., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.005 · Cited by 181
Self-citationPotential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180
N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks)
Schwalfenberg, G. (2021) · Journal of Nutrition and Metabolism · doi:10.1155/2021/9949453 · Cited by 198
Neuroinflammation and Oxidative Stress in Psychosis and Psychosis Risk
Barron, H., Hafizi, S., Andreazza, A. C., & Mizrahi, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030651 · Cited by 183
Berk, M., Dean, O. M., Cotton, S. M., Jeavons, S., Tanious, M., Kohlmann, K., Hewitt, K., Moss, K., Allwang, C., Schapkaitz, I., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08454 · Cited by 172
Self-citationMöller, M., du Preez, J. L., Viljoen, F. P., Berk, M., Emsley, R. A., & Harvey, B. H. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.12.011 · Cited by 168
Self-citationPowell, S. B., Sejnowski, T. J., & Behrens, M. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.049 · Cited by 164
Conus, P., Seidman, L. J., Fournier, M., Xin, L., Cleusix, M., Baumann, P., Ferrari, C., Cousins, A., Alameda, L., Gholam‐Rezaee, M., et al. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx093 · Cited by 164
Self-citationBehrens, M. M., & B, T. J. S. A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.002 · Cited by 163
Implications for reactive oxygen species in schizophrenia pathogenesis
Koga, M., Serritella, A. V., Sawa, A., & Sedlak, T. W. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.06.022 · Cited by 164
Do, K. Q., Cuenod, M., & Hensch, T. K. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv065 · Cited by 158
Self-citationNeuroimmune biomarkers in schizophrenia
Tomasik, J., Rahmoune, H., Guest, P. C., & Bahn, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.07.025 · Cited by 158
Gray Matter Deficits, Mismatch Negativity, and Outcomes in Schizophrenia
Rasser, P. E., Schall, U., Todd, J., Michie, P. T., Ward, P. B., Johnston, P., Helmbold, K., Case, V., Soyland, A., Tooney, P. A., et al. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp060 · Cited by 159
Light, G. A., & Swerdlow, N. R. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12730 · Cited by 158
Farokhnia, M., Azarkolah, A., Adinehfar, F., Khodaie-Ardakani, M.-R., Hosseini, S.-M.-R., Yekehtaz, H., Tabrizi, M., Rezaei, F., Salehi, B., Sadeghi, S.-M.-H., et al. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000001 · Cited by 155
Kantrowitz, J. T., Woods, S. W., Petkova, E., Cornblatt, B., Corcoran, C. M., Chen, H., Silipo, G., & Javitt, D. C. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00098-x · Cited by 148
Neuroinflammation in Schizophrenia: The Key Role of the WNT/β-Catenin Pathway
Vallée, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052810 · Cited by 156
Davis, J., Moylan, S., Harvey, B. H., Maes, M. H. J., & Berk, M. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414533012 · Cited by 145
Self-citationCarter, C. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn054 · Cited by 140
The effects of ketamine on the mismatch negativity (MMN) in humans - A meta-analysis.
Rosburg, T., & Kreitschmann-Andermahr, I. (2016) · Clinical Neurophysiology · doi:10.1016/j.clinph.2015.10.062 · Cited by 123
Cuénod, M., Steullet, P., Cabungcal, J.-H., Dwir, D., Khadimallah, I., Klauser, P., Conus, P., & Kim, Q. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01374-w · Cited by 134
Self-citationNeurobiology of Schizophrenia Spectrum Disorders: The Role of Oxidative Stress
Wood, S. J., Yücel, M., Pantelis, C., & Berk, M. (2009) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v38n5p396 · Cited by 127
Self-citationdas Neves Duarte, J. M., Kulak, A., Gholam-Razaee, M. M., Cuenod, M., Gruetter, R., & Do, K. Q. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.07.035 · Cited by 124
Kulak, A., Steullet, P., Cabungcal, J.-H., Werge, T., Ingason, A., Cuenod, M., & Do, K. Q. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4858 · Cited by 124
Self-citationKantrowitz, J. T., Epstein, M. L., Lee, M., Lehrfeld, N., Nolan, K. A., Shope, C., Petkova, E., Silipo, G., & Javitt, D. C. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.02.027 · Cited by 123
Baumann, P. S., Crespi, S., Marion‐Veyron, R., Solida, A., Thonney, J., Favrod, J., Bonsack, C., Kim, Q., & Conus, P. (2013) · Early Intervention in Psychiatry · doi:10.1111/eip.12037 · Cited by 123
Self-citationTakahashi, H., Rissling, A. J., Pascual-Marqui, R. D., Kirihara, K., Pela, M., Sprock, J., BRAFF, D. L., & Light, G. A. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.074 · Cited by 117
The relationship between preattentive sensory processing deficits and age in schizophrenia patients
Michael Kiang, A., BRAFF, D. L., Sprock, J., & Light, G. A. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.08.019 · Cited by 117
Lavoie, S., Chen, Y., Dalton, T. P., Gysin, R., Cuénod, M., Steullet, P., & Kim, Q. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05908.x · Cited by 118
Self-citationTargeting of NMDA receptors in new treatments for schizophrenia
Hashimoto, K. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.934225 · Cited by 117
Nagai, T., Tada, M., Kirihara, K., Araki, T., Jinde, S., & Kasai, K. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00115 · Cited by 115
Yolland, C. O. B., Hanratty, D., Neill, E., Rossell, S. L., Berk, M., Dean, O. M., Castle, D. J., Tan, E. J., Phillipou, A., Harris, A. W. F., et al. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419893439 · Cited by 112
Self-citationCognitive effects of adjunctive N-acetyl cysteine in psychosis
Rapado‐Castro, M., Dodd, S., Bush, A. I., Malhi, G. S., Skvarc, D., On, Z. X., Berk, M., & Dean, O. M. (2016) · Psychological Medicine · doi:10.1017/s0033291716002932 · Cited by 103
Self-citationPotential Roles of Redox Dysregulation in the Development of Schizophrenia
Perkins, D. O., Jeffries, C. D., & Do, K. Q. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.03.016 · Cited by 103
Brain foods - the role of diet in brain performance and health
Ekstrand, B., Scheers, N., Rasmussen, M. K., Young, J. F., Ross, A. B., & Landberg, R. (2020) · Nutrition Reviews · doi:10.1093/nutrit/nuaa091 · Cited by 115
Magalhães, P. V. D. S., Dean, O. M., Bush, A. I., Copolov, D., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson‐Hunt, M., & Berk, M. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.001 · Cited by 100
Self-citationRissling, A. J., Miyakoshi, M., Sugar, C. A., BRAFF, D. L., Makeig, S., & Light, G. A. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.09.006 · Cited by 100
Breier, A. F., Liffick, E., Hummer, T. A., Vohs, J. L., Yang, Z., Mehdiyoun, N. F., Visco, A. C., Metzler, E., Zhang, Y., & Francis, M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.03.012 · Cited by 99
Otte, D.-M., Sommersberg, B., Kudin, A., Guerrero, C., Albayram, Ö., Filiou, M. D., Frisch, P., Yilmaz, Ö., Drews, E., Turck, C. W., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.109 · Cited by 97
Sepehrmanesh, Z., Heidary, M., Akasheh, N., Akbari, H., & Heidary, M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.001 · Cited by 97
Oliver, G., Dean, O., Camfield, D., Blair-West, S., Ng, C., Berk, M., & Sarris, J. (2015) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2015.13.1.12 · Cited by 96
Self-citationBerk, M., Dean, O. M., Cotton, S., Gama, C. S., Kapczinski, F. P., Fernandes, B. S., Kohlmann, K., Jeavons, S., Hewitt, K., Moss, K., et al. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-91 · Cited by 96
Self-citationBrand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Mismatch negativity (MMN) as an index of central auditory system plasticity
Näätänen, R. (2008) · International Journal of Audiology · doi:10.1080/14992020802340116 · Cited by 100
Glutamatergic Modulation of Auditory Information Processing in the Human Brain
Gunduz-Bruce, H., Reinhart, R. M. G., Roach, B. J., Gueorguieva, R., Oliver, S., D'Souza, D. C., Ford, J. M., Krystal, J. H., & Mathalon, D. H. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.031 · Cited by 93
Dean, O. M., van den Buuse, M., Berk, M., Copolov, D., Mavros, C., & Bush, A. I. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.05.027 · Cited by 92
Self-citationMismatch negativity (MMN) as biomarker predicting psychosis in clinically at-risk individuals
Näätänen, R., Todd, J., & Schall, U. (2015) · Biological Psychology · doi:10.1016/j.biopsycho.2015.10.010 · Cited by 92
Glutathione Restores the Mechanism of Synaptic Plasticity in Aged Mice to That of the Adult
Robillard, J. M., Gordon, G. R., Choi, H. B., Christie, B. R., & MacVicar, B. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020676 · Cited by 89
Chengappa, K. N. R., Turkin, S. R., DeSanti, S., Bowie, C. R., Brar, J. S., Schlicht, P. J., Murphy, S. L., Hetrick, M. L., Bilder, R. M., & Fleet, D. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.10.001 · Cited by 86
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders
Bradlow, R. C. J., Berk, M., Kalivas, P. W., Back, S. E., & Kanaan, R. A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00907-3 · Cited by 87
Self-citationMismatch negativity (MMN) deficiency: A break-through biomarker in predicting psychosis onset
Näätänen, R., Shiga, T., Asano, S., & Yabe, H. (2015) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2014.12.012 · Cited by 82
Smaga, I., Pomierny, B., Krzyżanowska, W., Pomierny-Chamioło, L., Miszkiel, J., Niedzielska, E., Ogorka, A. Z. T., & Filip, M. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.018 · Cited by 86
Metadata
- Authors
- Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., Fornari, E., Meuli, R., Solida, A., Vianin, P., Cuénod, M., Buclin, T., & Do, K. Q.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- Mental Health Research Institute (AU)
- Monash University (AU)
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2007-11-14
- Volume
- 33
- Issue
- 9
- Pages
- 2187-2199
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2003906510
- Cited by
- 371
- References
- 67
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 4 · 2023: 15 · 2022: 10 · 2021: 22 · 2020: 21 · 2019: 33 · 2018: 16 · 2017: 27 · 2016: 19 · 2015: 28 · 2014: 31 · 2013: 23 · 2012: 28
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Own your potential (DEAKIN) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Stanley Medical Research Institute
- Centre d'Imagerie BioMédicale
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- N-acetylcysteine, glutathione, schizophrenia, mismatch negativity, NMDA receptor hypofunction, auditory evoked potentials, P300, auditory sensory processing, glutathione precursor
- MeSH terms
- Acetylcysteine, Acoustic Stimulation, Adult, Brain Mapping, Cerebral Cortex, Contingent Negative Variation, Discrimination, Psychological, Double-Blind Method, Electroencephalography, Evoked Potentials, Auditory, Female, Glutathione, Humans, Male, Middle Aged, Neuropsychological Tests, Reaction Time, Retrospective Studies, Schizophrenia, Time Factors, Free Radical Scavengers, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
